New behavioral program aims to curb HIV and drug use in High-Risk men
NCT ID NCT07281378
First seen Jun 24, 2026 · Last updated Jul 01, 2026 · Updated 3 times
Summary
This study tests a six-session behavioral program for stimulant-using men at high risk for HIV. The program focuses on positive thinking, mindfulness, and building supportive networks to help participants start taking PrEP (a daily pill that prevents HIV) and reduce stimulant use and risky sex. The trial will enroll 84 men across the U.S. to see if the program is feasible and acceptable.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tailored Positive Affect Intervention (behavioral counseling sessions)
What this could lead to
If it works, this could point toward an effective way to help stimulant-using men start PrEP and lower their HIV risk.
What could go wrong
This is a small pilot study (84 people) testing feasibility, not proof of effectiveness. Results may not apply broadly, and behavioral interventions can have mixed success.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PREP UPTAKE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••